TR201708567T4 - Sigma ligandların kemik kanseri ağrısında kullanımı. - Google Patents

Sigma ligandların kemik kanseri ağrısında kullanımı. Download PDF

Info

Publication number
TR201708567T4
TR201708567T4 TR2017/08567T TR201708567T TR201708567T4 TR 201708567 T4 TR201708567 T4 TR 201708567T4 TR 2017/08567 T TR2017/08567 T TR 2017/08567T TR 201708567 T TR201708567 T TR 201708567T TR 201708567 T4 TR201708567 T4 TR 201708567T4
Authority
TR
Turkey
Prior art keywords
bone cancer
cancer pain
sigma ligands
sigma
ligands
Prior art date
Application number
TR2017/08567T
Other languages
English (en)
Inventor
Miguel Vela-Hernández José
Plata-Salaman Carlos
Zamanillo-Castanedo Daniel
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of TR201708567T4 publication Critical patent/TR201708567T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Buluş, kemik kanseri ile bağlantılı ağrıyı önlemek ve/veya tedavi etmek için bir sigma ligandın, özellikle formül (I)'e sahip bir sigma ligandın kullanımı ile ilgilidir.
TR2017/08567T 2010-12-03 2011-12-02 Sigma ligandların kemik kanseri ağrısında kullanımı. TR201708567T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382330A EP2460519A1 (en) 2010-12-03 2010-12-03 Use of sigma ligands in bone cancer pain

Publications (1)

Publication Number Publication Date
TR201708567T4 true TR201708567T4 (tr) 2019-01-21

Family

ID=43629676

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/08567T TR201708567T4 (tr) 2010-12-03 2011-12-02 Sigma ligandların kemik kanseri ağrısında kullanımı.

Country Status (33)

Country Link
US (1) US20130324535A1 (tr)
EP (2) EP2460519A1 (tr)
JP (1) JP6027014B2 (tr)
KR (1) KR101855358B1 (tr)
CN (1) CN103313709B (tr)
AR (1) AR084730A1 (tr)
BR (1) BR112013013369A8 (tr)
CA (1) CA2819442C (tr)
CO (1) CO6781549A2 (tr)
CY (1) CY1119030T1 (tr)
DK (1) DK2646025T3 (tr)
ES (1) ES2626672T3 (tr)
HR (1) HRP20170818T1 (tr)
HU (1) HUE033488T2 (tr)
IL (1) IL226706A (tr)
LT (1) LT2646025T (tr)
MA (1) MA34878B1 (tr)
ME (1) ME02852B (tr)
MX (1) MX343773B (tr)
MY (1) MY171994A (tr)
NZ (1) NZ612119A (tr)
PL (1) PL2646025T3 (tr)
PT (1) PT2646025T (tr)
RS (1) RS56081B1 (tr)
RU (1) RU2585095C2 (tr)
SG (1) SG190745A1 (tr)
SI (1) SI2646025T1 (tr)
TN (1) TN2013000227A1 (tr)
TR (1) TR201708567T4 (tr)
TW (1) TWI629060B (tr)
UA (1) UA112638C2 (tr)
WO (1) WO2012072782A1 (tr)
ZA (1) ZA201304966B (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
WO2015036470A1 (en) * 2013-09-12 2015-03-19 Laboratorios Del Dr. Esteve, S.A. Nsaid and sigma receptor ligand combinations
TN2016000229A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr Gabapentinoids and sigma receptor ligands combinations.
TN2016000228A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS.
EP2929883A1 (en) * 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
TW201806601A (zh) * 2016-07-12 2018-03-01 以斯提夫博士實驗室股份有限公司 σ受體配體在皰疹後遺疼痛中的用途
JP2021525251A (ja) * 2018-05-21 2021-09-24 イプセン バイオファーム リミテッドＩｐｓｅｎ Ｂｉｏｐｈａｒｍ Ｌｉｍｉｔｅｄ 骨癌誘発性アロディニアの抑制
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
KR20210151572A (ko) 2020-06-05 2021-12-14 주식회사 허밍아비스 발열체 조성물 및 이를 이용한 마스크 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4838121B2 (ja) * 2003-06-26 2011-12-14 ノバルティス アーゲー ５員ヘテロ環を基礎とするｐ３８キナーゼ阻害剤
DK1781618T3 (da) * 2004-08-27 2012-10-29 Esteve Labor Dr Sigma-receptorinhibitorer
CA2576144C (en) * 2004-08-27 2012-12-11 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
CA2641144A1 (en) * 2006-03-01 2007-09-07 Rosa Cuberes-Altisent Pyrazole derivatives as sigma receptor inhibitors
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

Also Published As

Publication number Publication date
CA2819442A1 (en) 2012-06-07
TW201249805A (en) 2012-12-16
AR084730A1 (es) 2013-06-05
US20130324535A1 (en) 2013-12-05
AU2011334880A1 (en) 2013-07-11
MA34878B1 (fr) 2014-02-01
MX2013006140A (es) 2013-07-03
KR101855358B1 (ko) 2018-05-04
TWI629060B (zh) 2018-07-11
RS56081B1 (sr) 2017-10-31
HUE033488T2 (en) 2017-12-28
SG190745A1 (en) 2013-07-31
EP2460519A1 (en) 2012-06-06
ES2626672T3 (es) 2017-07-25
DK2646025T3 (en) 2017-06-06
SI2646025T1 (sl) 2017-07-31
CN103313709B (zh) 2017-05-24
IL226706A (en) 2015-07-30
CY1119030T1 (el) 2018-01-10
ME02852B (me) 2018-04-20
RU2013130222A (ru) 2015-01-10
CA2819442C (en) 2018-06-12
RU2585095C2 (ru) 2016-05-27
ZA201304966B (en) 2014-09-25
NZ612119A (en) 2014-06-27
EP2646025B1 (en) 2017-03-15
JP2014501732A (ja) 2014-01-23
HRP20170818T1 (hr) 2017-08-25
EP2646025A1 (en) 2013-10-09
PT2646025T (pt) 2017-06-26
MY171994A (en) 2019-11-11
TN2013000227A1 (en) 2014-11-10
CO6781549A2 (es) 2013-10-31
BR112013013369A2 (pt) 2016-09-06
BR112013013369A8 (pt) 2018-01-09
JP6027014B2 (ja) 2016-11-16
MX343773B (es) 2016-11-23
LT2646025T (lt) 2017-06-12
CN103313709A (zh) 2013-09-18
PL2646025T3 (pl) 2017-09-29
AU2011334880B2 (en) 2016-09-15
KR20130135881A (ko) 2013-12-11
WO2012072782A1 (en) 2012-06-07
UA112638C2 (uk) 2016-10-10

Similar Documents

Publication Publication Date Title
TR201708567T4 (tr) Sigma ligandların kemik kanseri ağrısında kullanımı.
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
TR201903981T4 (tr) Kanser tedavisi için bileşikler.
CO6680628A2 (es) Uso de ligandos sigma en la hiperalgesia inducida por opioides
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
EA201171367A1 (ru) Винилиндазолильные соединения
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
BR112015011830A2 (pt) compostos e seus métodos de utilização
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201400178A1 (ru) Лечение рака молочной железы
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
NZ744862A (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafenib
UA111148C2 (uk) Сигма-ліганди для застосування при профілактиці і/або лікуванні післяопераційного болю
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
IN2014DN09228A (tr)
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
TR201909522T4 (tr) Anti-tümör aktivitesine sahip bir nonapeptit.
CR20140367A (es) Inhibidores de iap
MX342947B (es) Tratamiento de diabetes tipo 2.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
MX336761B (es) Compuestos para el tratamiento de cancer.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.